Howard G. Welgus sold $143k of ARQT
director at Arcutis Biotherapeutics, Inc.. 10,000 shares at an average of $14.30, traded Aug 1, 2025, filed Aug 5, 2025.
Score components
- +15RoleDirector
- +11Trade size$143k at market
- 0Share of holdings soldSold 9.4% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.8%, 3m +56.7%, 6m +70.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001787306-25-000115, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 1, 2025 | MOption exercise Common Stock10b5-1 | +6,110 | $0.00 | $0 | 106,316 | Aug 5, 2025 |
| Aug 1, 2025 | SOpen-market sale Common Stock10b5-1 | -6,110 | $14.30 | $87k | 100,206 | Aug 5, 2025 |
| Aug 1, 2025 | MOption exercise Common Stock10b5-1 | +3,890 | $0.00 | $0 | 104,096 | Aug 5, 2025 |
| Aug 1, 2025 | SOpen-market sale Common Stock10b5-1 | -3,890 | $14.30 | $56k | 100,206 | Aug 5, 2025 |
| Aug 1, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,110 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,890 | $0.00 | $0 | 0 | Aug 5, 2025 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $116k 4,731 shares | -11% | |
| 18Weak | Arcutis Biotherapeutics, Inc. | Sue-Jean Lin director | $121k 4,946 shares | -15% | |
| 10Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $4,673 222 shares | -0% | |
| 17Weak | Arcutis Biotherapeutics, Inc. | Latha Vairavan SVP Chief Financial Officer | $9,157 435 shares | -1% | |
| 10Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $16k 684 shares | -1% | |
| 22Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $192k 8,256 shares | -6% | |
| 18Weak | Arcutis Biotherapeutics, Inc. | Todd Watanabe See Remarks | $75k 3,172 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.